Skip to main content
    L

    Labcorp Holdings Inc. (LH)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $372.49
    +2.01 (+0.54%)

    Market Cap: $30.08B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Labcorp Holdings Inc. (LH) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Labcorp Holdings (LH) trades at 20.6x trailing earnings and 2.1x sales. Its P/E of 20.6x is above its 5-year median of 15.3x. Its forward P/E is 20.0x. The median P/E across 11 similar companies is 31.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 3.0% higher over the next year. Its free cash flow yield is 4.3%.

    MultipleValue
    P/E (trailing)20.6x
    Forward P/E20.0x
    Price to sales2.1x
    Price to book3.4x
    EV/EBITDA17.7x
    Price to FCF23.5x
    EV/FCF27.8x
    PEG1.6
    FCF yield4.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 34.6% above 15.3x, its P/S is 31.3% above 1.6x and its P/B is 41.7% above 2.4x.

    MultipleCurrent5-year median10-year median
    P/E20.6x15.3x15.3x
    P/S2.1x1.6x1.6x
    P/B3.4x2.4x2.4x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 8.5x in 2020 to 16.6x in 2017.

    Year endPriceP/EP/SP/B
    2025$250.8815.3x1.5x2.4x
    2024$229.3215.7x1.5x2.4x
    2023$227.2916.3x1.6x2.5x
    2022$235.4811.8x1.8x2.1x
    2021$314.2111.0x2.3x2.9x
    2020$203.558.5x1.4x2.1x
    2019$169.1715.0x1.4x2.2x
    2018$126.3611.5x1.1x1.8x
    2017$159.5116.6x1.6x2.4x
    2016$128.3814.7x1.4x2.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LH

    What is LH's forward P/E ratio?

    Labcorp Holdings has a forward P/E ratio of 20.0x.

    Is LH stock overvalued?

    GNG's valuation label for LH is Fairly valued. Its P/E of 20.6x compares with a median of 31.5x across 11 similar companies.

    What is LH's price to sales ratio?

    Labcorp Holdings has a price to sales ratio of 2.1x.

    What is Labcorp Holdings's average P/E ratio over 5 years?

    Labcorp Holdings's median P/E over the last 5 years is 15.3x, from 60 month-end values through Oct 2026.

    What is LH's PEG ratio?

    Labcorp Holdings has a PEG ratio of 1.6.